Evidence map›Paper›PMID 37021282›Full record

ArticleFrontiers in neurology2023

Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related stroke.

Morin Beyeler, Lorenz Grunder, Jayan Göcmen, Fabienne Steinauer, Nebiyat F Belachew, Moritz Kielkopf, Leander Clénin, Madlaine Mueller, Norbert Silimon, Christoph Kurmann and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 3 countries.

Morin BeyelerDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Lorenz GrunderInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Jayan GöcmenDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Fabienne SteinauerDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Nebiyat F BelachewDepartment of Neuroradiology, University Hospital, Freiburg, Germany.
Moritz KielkopfDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Leander CléninDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Madlaine MuellerDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Norbert SilimonDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Christoph KurmannInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Thomas MeinelDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Philipp BückeDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
David SeiffgeDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Tomas DobrockyInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Eike I PiechowiakInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Sara Pilgram-PastorInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Heinrich P MattleDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Babak B NaviClinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY, United States.
Marcel ArnoldDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Urs FischerDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Jan GrallaInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Martin D BergerDepartment of Medical Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Simon JungDepartment of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
Johannes KaesmacherInstitute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
University of Bern · CHUniversity Hospital of Bern · CHUniversity Medical Center Freiburg · DEUniversity of Basel · CHWeill Cornell Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Identification of paraneoplastic hypercoagulability in stroke patients helps to guide investigations and prevent stroke recurrence. A previous study demonstrated an association between the absence of the susceptibility vessel sign (SVS) on brain MRI and active cancer in patients treated with mechanical thrombectomy. The present study aimed to confirm this finding and assess an association between the absence of the hyperdense vessel sign (HVS) on head CT and active cancer in all stroke patients. Methods: SVS and HVS status on baseline imaging were retrospectively assessed in all consecutive stroke patients treated at a comprehensive stroke center between 2015 and 2020. Active cancer, known at the time of stroke or diagnosed within 1 year after stroke (occult cancer), was identified. Adjusted odds ratios (aOR) and their 95% confidence interval (CI) for the association between the thrombus imaging characteristics and cancer were calculated using multivariable logistic regression. Results: Of the 2,256 patients with thrombus imaging characteristics available at baseline, 161 had an active cancer (7.1%), of which 36 were occult at the time of index stroke (1.6% of the total). The absence of SVS was associated with active cancer (aOR 3.14, 95% CI 1.45-6.80). No significance was reached for the subgroup of occult cancer (aOR 3.20, 95% CI 0.73-13.94). No association was found between the absence of HVS and active cancer (aOR 1.07, 95% CI 0.54-2.11). Conclusion: The absence of SVS but not HVS could help to identify paraneoplastic hypercoagulability in stroke patients with active cancer and guide patient care.

Indexed as

cancer-related strokehyperdense vessel signmalignancy-related strokesusceptibility vessel signthrombus imaging characteristics

Identifiers

PMID37021282
PMCPMC10067593
OpenAlexW4327980526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.